Euglycemic diabetic ketoacidosis in a patient on sodium-glucose cotransporter 2 inhibitors.
| Autor: | Hammond DB; Daniel B. Hammond is director of admissions and recruitment for the PA program at the University of California San Diego. Claire C. Ingram is an instructor in the Division of Endocrinology, Metabolism, and Diabetes and the Section of Maternal-Fetal Medicine at the University of Colorado School of Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise., Ingram CC |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JAAPA : official journal of the American Academy of Physician Assistants [JAAPA] 2023 Sep 01; Vol. 36 (9), pp. 1-3. |
| DOI: | 10.1097/01.JAA.0000937256.39070.5d |
| Abstrakt: | Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel drug class for treating type 2 diabetes and are unique among diabetes medications because they increase urinary glucose excretion. SGLT2 inhibitors also have shown benefit beyond reducing blood glucose in patients with cardiovascular disease, renal disease, or heart failure. The American Diabetes Association recommends SGLT2 inhibitors for patients with type 2 diabetes who have one or more of these comorbidities. This article discusses one life-threatening adverse reaction to SGLT2 inhibitors, euglycemic diabetic ketoacidosis, and recommendations about patients on SGLT2 inhibitors who need surgery. (Copyright © 2023 American Academy of Physician Associates.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|